Last reviewed · How we verify
NCT03425461
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Phase 1 trial testing Anti-SEMA4D Monoclonal Antibody VX15/2503 in Metastatic Melanoma in 6 participants. Terminated before completion.
4 March 2021
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 14 June 2018 |
| Primary completion | 4 March 2021 |
| Estimated completion | 4 March 2021 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Anti-SEMA4D Monoclonal Antibody VX15/2503
- Ipilimumab — full drug profile →
- Laboratory Biomarker Analysis
- Nivolumab (nivolumab) — full drug profile →
- Pharmacological Study — full drug profile →
Conditions studied
- Metastatic Melanoma — all drugs for Metastatic Melanoma →
- Stage III Cutaneous Melanoma AJCC v7 — all drugs for Stage III Cutaneous Melanoma AJCC v7 →
- Stage IIIA Cutaneous Melanoma AJCC v7 — all drugs for Stage IIIA Cutaneous Melanoma AJCC v7 →
- Stage IIIB Cutaneous Melanoma AJCC v7 — all drugs for Stage IIIB Cutaneous Melanoma AJCC v7 →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
18 and older, any sex, with Metastatic Melanoma or Stage III Cutaneous Melanoma AJCC v7. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized pilot phase I trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 when given together with nivolumab or ipilimumab in treating patients with stage III or IV melanoma. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.
Peranzoni E, Ingangi V, Masetto E, Pinton L, et al · · 2020 · cited 60× · PMID 32793228 · DOI 10.3389/fimmu.2020.01590 -
Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers.
Hui DHF, Tam KJ, Jiao IZF, Ong CJ. · · 2019 · cited 29× · PMID 30759745 · DOI 10.3390/ijms20030774 -
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.
· 2018 · cited 18× · PMID 30400822 · DOI 10.1186/s40425-018-0423-x -
Semaphorins as Potential Immune Therapeutic Targets for Cancer.
Jiang J, Zhang F, Wan Y, Fang K, et al · · 2022 · cited 10× · PMID 35155237 · DOI 10.3389/fonc.2022.793805 -
SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia.
Valentini E, Di Martile M, Del Bufalo D, D'Aguanno S. · · 2021 · cited 9× · PMID 33858502 · DOI 10.1186/s13046-021-01929-3 -
Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model.
Mao Y, Evans EE, Mishra V, Balch L, et al · · 2021 · cited 8× · PMID 34502373 · DOI 10.3390/ijms22179465
Verify or expand the search:
- PubMed search for NCT03425461
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-SEMA4D Monoclonal Antibody VX15/2503
Trials testing the same drug.
- NCT03373188 — VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer · Phase 1 · completed
Other recruiting trials for Metastatic Melanoma
Currently open trials in the same condition.
- NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
- NCT07237100 — Mirdametinib in Patients With Advanced NF1-mutant Melanoma · Phase 2 · recruiting
- NCT07086105 — A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma · Phase 1 · recruiting
- NCT07112170 — Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma · NA · recruiting
- NCT06488365 — In Vivo Liquid Biopsy of Melanoma (Cytophone) · NA · recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03425461 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 2 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03425461.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing